

IMMUNOLOGY SECTION

Objectives

Tumor immunology

To understand tumor-immune interactions in the microenvironment and apply this understanding to:

1. Identify prognostic markers in cancer (cancer progression/chemo-radio-resistance/immunosuppression)
2. Develop immunotherapies that strengthen the immune system and can be used as adjuvants in cancer treatment along with chemo/radio therapies


Low dose radio biology

To understand the

1. Effects of low dose radiation on the immune system
2. Effects of diagnostic/medical exposures on DNA damage response, immune response and antioxidant status in cancer

Immunosuppressive Tumor microenvironment

- Tumor secretes mediators like PGE2
- Immune cells are dysfunctional
- Immune cells secrete T cell suppressive cytokines like TGF- β and IL-10
- Radiotherapy increases secretion of TGF- β



Immunostimulatory Tumor microenvironment

- Immune cells are functional and can directly kill the tumor cells through cell-cell contact
- They can also kill the tumor cells through mediators like nitric oxide.

1. Identify prognostic markers in cancer

Cancer progression

(a) A novel 15 gene signature was identified from macrophage-tumor interactions in breast cancer and has prognostic significance

8 gene set identified by macrophage-tumor interactions

(TNF- α , IL-6, IL-1 β , MMP1, MMP9, TGF- β 1, TGF β RII, EGFR)

Enrichment genes with significant co-occurrence

(TP53, WTAPP1, SLC12A5, PSAT1, ESR1, TPD52, PRKCD)


15 Gene signature

Altered in 63.6% TCGA samples

Cancer radioresistance

(b) TGF- β signaling was increased in radioresistant breast cancer cells resulting in hybrid epithelial-mesenchymal phenotype and enrichment of cancer stem cells

Increased TGF- β in radioresistant cells



Increased tumor formation of radioresistant cells in SCID mice




Immunosuppression

(c) Tumor induced alterations in miRNAs can serve as markers of dendritic cells with lowered immunogenicity

miRNA profile (iDC TCM vs iDC)


□ RNA-seq ■ RT-PCR



miR-155-5p, miR-155-3p and miR-146a-3p Upregulated in dysfunctional DC


miR-362-2-5p, miR-187-3p and miR-142a-3p Downregulated in dysfunctional DC

(2.a) Molecules tested as immunotherapeutics in pre-clinical models:



G1-4A, polysaccharide from *T.cordifolia* induced killer Dendritic cell phenotype and DC mediated reduction of tumor burden in Lymphoma model

Pandey et al, Int. Immunophar, 2012,2014



COX-2 Inhibitor **NS-398** abrogated tumor induced DC dysfunction and decreased tumor burden in Lymphoma model


Pandey et al, Immunology letters, 2017

TGF-β Receptor I inhibitor SB431542 inhibited Breg-Treg axis and reduced tumor burden in Fibrosarcoma model

(2.b) Molecules tested as immunotherapeutics in cell culture systems


**PD98059
(MEK inhibitor)**

(1) ERK inhibitor abrogated TRAIL induced increase in epithelial-mesenchymal transition in lung cancer cell lines with mutant KRAS




Pal et al, Cancer microenvironment, 2016

(2) ERK inhibitor abrogated macrophage induced increase in epithelial-mesenchymal transition; cancer stem cells; migration and invasion of breast cancer cells.



**Sulphoraphane
(derived from broccoli)**

(3) Sulforaphane up-regulated NKG2D ligands in lung cancer cell lines thereby activating NK cell-mediated killing.



Amin and Shankar, LifeSciences, 2015

c) Molecules being screened as immunotherapeutics

(1) Epigenetic drug library for identification of inhibitors of T regulatory cell differentiation

(2) FDA approved drug library for identification of COX-2 inhibitors

B. Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tissues of cancer patients: a prospective *in-vivo* study

Principal Investigator: Dr. R. Badwe, Director, TMC






Lead Investigators from BARC: [Dr. Birajalaxmi Das](#), Head, LLRRS; [Dr. Bhavani Shankar](#), Head, Immunology Section

Lead Investigators ACTREC : Dr. Jayant S. Goda, Dr. Supriya J. Sastri, Dr. Sarbani Ghosh Laskar, Dr. Sudeep Gupta, Dr. S. Chiplunkar

Objective: To determine the effects of medical exposures (diagnostic/therapeutic) in blood cells and tissues of normal & cancer patients using multiple endpoints.

PBMC

- **DNA damage and repair studies** : Analysis of γ -H2AX (positive cells/foci) by flow cytometry and fluorescence microscopy
- **Immune response** : Cytokine expression by ELISPOT and ELISA
- **Gene expression profile** : DNA Damage Response and DNA repair genes by RT-qPCR
- **Antioxidant status**: Lipid peroxidation, lactate dehydrogenase, and levels of Antioxidant enzyme status




Tumor tissues


- Transcriptome sequencing
- Exome sequencing
- miRNA sequencing

Collaborative project
with TMH-ACTREC

FLOW CYTOMETER




- Provides simultaneous multi-parameter analysis of single cells



Proliferation by CFSE dilution in CD4⁺ T cells

- Cell-cell interaction in co-culture




Immune cell mediated tumor killing in co-culture

IMAGING CYTOMETER




- Combines advantages of microscopy and cytometry for high-throughput cellular analysis
- Multichannel digital images of hundreds of thousands of individual cells can be captured within minutes
- Can obtain single-cell morphological and intracellular localization measurements of different cell markers

Phagocytosis of E.coli Bioparticle by macrophages



Proliferation of B cells in tumor



ELISPOT READER



- Measures the frequency of cytokine-secreting cells at the single-cell level.
- Each spot corresponds to an individual cytokine-secreting cell.
- Very sensitive and can detect frequencies in $<10^4$ cells

ELISpot read-out of cytokine secreting cells

